Discontinued drug therapies to treat diabetes in 2015

Expert Opinion on Investigational Drugs

Volumn 26, Issue 2, 2017, Pages 219-225

  Hedrington, Maka S ^a   Davis, Stephen N ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

diabetes; diabetes nephropathy; discontinued drug; insulin; Peglispro

Indexed keywords

ANTIDIABETIC AGENT; BIOD 238; BIOD 250; INSULIN PEGLISPRO; SHORT ACTING INSULIN; UNCLASSIFIED DRUG; NEW DRUG;

ARTICLE; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC STOMACH PARESIS; DRUG THERAPY; DRUG WITHDRAWAL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; ANIMAL; DRUG DESIGN; TREATMENT OUTCOME;

ANIMALS; DIABETES MELLITUS; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; HYPOGLYCEMIC AGENTS; TREATMENT OUTCOME;

EID: 85007402177     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1080/13543784.2017.1274732     Document Type: Article

References (48)

1. FDA. FDA-approved diabetes medicines. Silver Spring, (MD):U.S. Food and Drug Administration. 2016
2. Karagiannis T, Liakos A, Bekiari E, et al. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes:a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2015;17:1065–1074.•• A good review of long acting glucagon-like peptide 1 receptor agonists.
3. Ryan D, Acosta A., GLP-1 receptor agonists:nonglycemic clinical effects in weight loss and beyond. Obesity (Silver Spring). 2015;23:1119–1129.
4. Financial statement for 2015 [press release]. 3Feb 2016 2016
5. Nordisk N, - a Focused Healthcare Company [press release]. 2015
6. Kosinski JR, Hubert J, Carrington PE, et al. The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin. Obesity (Silver Spring). 2012;20:1566–1571.
7. Day JW, Ottaway N, Patterson JT, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009;5:749–757.
8. Skow MA, Bergmann NC, Knop FK., Diabetes and obesity treatment based on dual incretin receptor activation:‘twincretins’. Diabetes Obes Metab. 2016; 18:847–854.• A good description of recent advances in the field of dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonism.
9. Pocai A, Carrington PE, Adams JR, et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes. 2009;58:2258–2266.
10. Stewart PM, Krozowski ZS., 11β-Hydroxysteroid dehydrogenase. Vitam Horm. 1999;57:249–324.
11. Smas CM, Chen L, Zhao L, et al. Transcriptional repression of pref-1 by glucocorticoids promotes 3T3-L1 adipocyte differentiation. J Biol Chem. 1999;274:12632–12641.
12. Kraus-Friedmann N., Hormonal regulation of hepatic gluconeogenesis. Physiol Rev. 1984;64:170–259.
13. Djurhuus CB, Gravholt CH, Nielsen S, et al. Effects of cortisol on lipolysis and regional interstitial glycerol levels in humans. Am J Physiol Endocrinol Metab. 2002;283:E172–7.
14. Veniant MM, Hale C, Komorowski R, et al. Time of the day for 11β-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice. Diabetes Obes Metab. 2009;11:109–117.
15. Hermanowski-Vosatka A, Balkovec JM, Cheng K, et al. 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med. 2005;202:517–527.
16. Rosenstock J, Banarer S, Fonseca VA, et al. The 11-Beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care. 2010;33:1516–1522.
17. Pharmaceuticals V. vitae pharmaceuticals reports top-line results from remaining monotherapy arm of phase 2 clinical trial of bi187004 in overweight type 2 diabetes patients. 2015.
18. Amin NB, Aggarwal N, Pall D, et al. Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes Obesity & Metabolism. 2015;17:751–759.
19. Luo DX, Tong DJ, Rajput S, et al. Targeting acetyl-coa carboxylases:small molecular inhibitors and their therapeutic potential. Recent Pat Anti-Canc. 2012;7:168–184.
20. Bourbeau MP, Bartberger MD. Recent advances in the development of acetyl-CoA carboxylase (ACC) inhibitors for the treatment of metabolic disease. J Med Chem. 2015;58:525–536.• Description of the recent progress made in the development of acetyl-CoA carboxylase inhibitors.
21. Sinha VP, Howey DC, Choi SL, et al. Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2014;16:344–350.
22. Davies MJ, Russell-Jones D, Selam JL, et al. Basal insulin peglispro vs insulin glargine in insulin-naive type 2 diabetes:IMAGINE 2 randomized trial. Diabetes Obes Metab. 2016;18:1055–1064.
23. Analog-based ultra-rapid-acting insulin [press release]
24. Development of additional RHI- and Insulin analog-based formulations [press release]. 2015
25. Gross JL, De Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy:diagnosis, prevention, and treatment. Diabetes Care. 2005;28:164–176.
26. Cameron KO, Kung DW, Kalgutkar AS, et al. Discovery and preclinical characterization of 6-chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1h-indole-3-carboxylic acid (pf-06409577), a direct activator of adenosine monophosphate-activated protein kinase (ampk), for the potential treatment of diabetic nephropathy. J Med Chem 2016;59:8068–8081.
27. Goteti KMS, Webster R, Gilbert S, et al. Pharmacokinetics and pharmacodynamics of a chemokine CCR2/5 receptor antagonist (pf-04634817) administered daily in adults with type 2 diabetes and overt nephropathy. Clinical Pharmacology & Therapeutics 2016 Feb 1;99:S66–S.
28. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort:the Rochester Diabetic Neuropathy Study. Neurology. 1993;43:817–824.
29. Dyck PJ, Litchy WJ, Lehman KA, et al. Variables influencing neuropathic endpoints:the Rochester Diabetic Neuropathy Study of healthy subjects. Neurology. 1995;45:1115–1121.
30. Edwards JL, Vincent AM, Cheng HT, et al. Diabetic neuropathy:mechanisms to management. Pharmacol Ther. 2008;120:1–34
31. Jucaite A, Takano A, Bostrom E, et al. AZD5213:a novel histamine H3 receptor antagonist permitting high daytime and low nocturnal H3 receptor occupancy, a PET study in human subjects. Int J Neuropsychopharmacol. 2013;16:1231–1239.
32. Rodgers KE, Bolton LL, Verco S, et al. NorLeu3-angiotensin (1-7) [dsc127] as a therapy for the healing of diabetic foot ulcers. Adv Wound Care (New Rochelle). 2015;4:339–345.
33. Rodgers KE, Espinoza T, Felix J, et al. Acceleration of healing, reduction of fibrotic scar, and normalization of tissue architecture by an angiotensin analogue, NorLeu3-A(1-7). Plast Reconstr Surg. 2003;111:1195–1206.
34. Balingit PP, Armstrong DG, Reyzelman AM, et al. NorLeu3-A(1-7) stimulation of diabetic foot ulcer healing:results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial. Wound Repair Regen. 2012;20:482–490.
35. Comvita. Derma Sciences halts phase III clinical trial. 2015.
36. Kotronen A, Seppälä-Lindroos A, Bergholm R, et al. Tissue specificity of insulin resistance in humans:fat in the liver rather than muscle is associated with features of the metabolic syndrome. Diabetologia. 2008;51:130–138.
37. Riddle MC., Lessons from peglispro:IMAGINEhow to improve drug development and affordability. Diabetes Care. 2016;39:499–501.•• Good description of possible reasons behind termination of insulin peglispro.
38. Kawai F., Microbial degradation of polyethers. Appl Microbiol Biot. 2002;58:30–38.
39. Veronese FM. Peptide and protein PEGylation:a review of problems and solutions. Biomaterials. 2001;22:405–417.
40. Hennekens CH, Hebert PR, Schneider WR, et al. Academic perspectives on the United States Food and Drug Administration’s guidance for industry on diabetes mellitus. Contemp Clin Trials. 2010;31:411–413.
41. Colca JR. Discontinued drugs in 2006:renal, endocrine and metabolic drugs. Expert Opin Investig Drugs. 2007;16:1517–1523.
42. Harper M. More proof FDA is faster than other drug regulators. Available from:http://www.forbes.com/sites/matthewherper/2012/06/19/more-proof-fda-is-faster-than-other-regulators/#411219926629
43. Forbes. More proof FDA is faster than other drug regulators
44. Practice BTP. Biopharmaceutical industry-sponsored clinical trials:impact on state economies. Pharmaceutical Research and Manufacturers of America. 2015
45. Development TCftSoD. Tufts new estimate of costs to bring a drug to market & beyond. 2014
46. Hedrington MS, Davis SN. Discontinued in 2013:diabetic drugs. Expert Opin Investig Drugs. 2014;23:1703–1711
47. Colca JR. Discontinued drug therapies to treat diabetes in 2014. Expert Opin Investig Drugs. 2015;24:1241–1245.
48. Lièvre M, Ménard J, Bruckert E, et al. Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility. BMJ. 2001;322:603–605.